Table 1.
DNA sequences of oligonucleotides used in polymerase chain reactions to detect carbapenemase and outer-membrane proteins of A. baumannii isolates.
Table 2.
Minimum inhibitory concentration of antibiotics and resistance mechanisms of 20 A. baumannii isolates.
Table 3.
Determination of minimum inhibitory concentration by microdilution, resistance genes, and molecular profile of six A. baumannii isolates.
Table 4.
Results of the three different methods (FICI, 2-well, and time-kill assay) used to evaluate in vitro synergism of antibiotic combinations against 20 A. baumannii isolates.
Table 5.
In vitro synergistic effect, according to two different methods (FICI and 2-well) of antimicrobial combinations against 20 isolates of multi-drug resistant Acinetobacter baumannii.
Fig 1.
Time-kill curve of isolates using drugs alone and in combination at 1 x MIC and 0.5 x MIC, respectively, against an A. baumannii isolate.
(A) Isolate 23 –Colistin (16 and 8 mg/L)/Vancomycin (64 and 32mg/L), (B) Isolate 28—Colistin (8 and 4 mg/L)/Rifampicin (4 and 2mg/L), (C) Isolate 1—Imipenem (256 and 128mg/L)/Tigecycline (1 and 0.5mg/L), (D) Isolate 5—Fosfomycin (128 and 64mg/L)/Amikacin (64 and 32mg/L).
Table 6.
Clinical, demographic, and vancomycin time-kill synergism data of 18 patients colonized and infected by multidrug-resistant Acinetobacter baumannii.